New Horizons in the Treatment of Osteosarcoma
Author:
Affiliation:
1. From the Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD (P.S.M.); and the Osteosarcoma Institute, Dallas (L.J.H.).
Publisher
Massachusetts Medical Society
Subject
General Medicine
Link
http://www.nejm.org/doi/pdf/10.1056/NEJMra2103423
Cited by 194 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma;International Journal of Pharmaceutics;2024-03
2. Ceramide metabolism-related prognostic signature and immunosuppressive function of ST3GAL1 in osteosarcoma;Translational Oncology;2024-02
3. Circular RNA CircSATB2 facilitates osteosarcoma progression through regulating the miR-661/FUS-mediated mRNA of ZNFX1;Cellular Signalling;2024-02
4. Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma;Journal of Bone Oncology;2024-02
5. Essential genes analysis reveals small ribosomal subunit protein eS28 may be a prognostic factor and potential vulnerability in osteosarcoma;Journal of Bone Oncology;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3